eve Conference Variant Block
- Mr. Zhenyu XUAN, PhD
- Company: Suzhou Youseen New Drug R&D Co. Ltd.
- Title: General Manager of Suzhou Youseen New Drug R&D Co.
- Topic: CRO Service for Traditional Chinese Medicine Development and the Entrance of TCM into Global Market
- Introduction:
- General Manager of Suzhou Youseen New Drug R&D Co. Ltd., Senior Engineer; Professor of Shanghai University of TCM; Shanghai excellent academic leader Air Jordan News
- Mr. Dan ZHANG
- Company: Fountain Medical Development Ltd.
- Title: President and CEO of Fountain Medical Development
- Topic: Managing Safety Issues in Clinical Development in China: The Role of CRO
- Introduction:
- Dr. Dan Zhang has more than 15 year of drug development experience. He is the Chairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with primary operation in South East Asia and China. FMD operates the largest Phase I unit in China, and the largest central lab in China as well, along with phase II/III operations in mainland China, Hong Kong, Taiwan and South Korea, and the full support of regulatory affairs, data management and biostatistics, EDC and pharmacoeconomics operation. Nike Odyssey React
- Mr. James J. HO, MD, PhD, DABCC
- Company: Beijing Lawke Health laboratory Co. Ltd.
- Title:
- Topic: Who Sets the Rules -- Chinese CRO Central Lab Going International
- Introduction:
- Professor, Director of Peking Union Medical College & Chinese Academy of Medical Sciences, Center for Clinical Laboratory Development; Chairman and CEO of Beijing Lawke Health laboratory Co. Ltd. SNEAKERS
- Ms. Lin HE, PhD
- Company: Shanghai Pharmaceutical Clinical Research Center
- Title: Senior Director of Strategic Development Departmen
- Topic: China and Global CRO Industrial Development Trends
- Introduction:
- •PhD of Biology, Tuebingen University in Germany •2 years’ working experience of R&D coordinator in Novartis China •12 years’ working experience in Marketing Planning, Business Development of Wyeth Pharmaceutical China and Clinical R&D Planning for Asia-Pacific in Wyeth Research. Puma
- Mr. Tony SONG
- Company: 3M
- Title: Manager of Life Science Market in 3M Purification
- Topic: Filtration Technologies in Pharmaceutical R&D Phase and 3M Validation Service
- Introduction:
- He holds a Master degree in Bioengineering from Zhejiang University. He is Manager of Life Science Market in 3M Purification division. He has worked as QA manager in Jiangzhong Caoshanhu Pharm, a specialist in the development of new membrane material and process. He also is the Guest Lecturer in CFDAIA Air Jordan 2017 Casual Shoes
- Mr. Charlie XU, MD, PhD
- Company: Frontage Lab China
- Title: VP of Clinical Services at Frontage Lab China
- Topic: Clinical CROs in China -- Prospective and Globalization
- Introduction:
- Dr. Chun（Charlie）Xu has over 25 years of medical practice, academic research, and industry experiences in China, Canada, and the U.S. After graduation from Capital University of Medicine in Beijing in 1982, Charlie worked as a resident physician in Beijing Tiantan Hospital for 5 years and then moved to Canada in 1987 to start an academic career as a prestigious Jeanne Timmins Scholar at Montreal Neurological Institute. He then received his PhD in neuropathology from McGill in 1997 and a post-doctorate in pathogenesis of Alzheimer’s disease at Montreal General Hospital. New Nike Shoes
- Mr. Zhenping WU, PhD, M.B.A.
- Company: HMP
- Title: Senior VP of Pharmaceutical Sciences at HMP
- Topic: Selection Criteria for Contract Organizations -- An Insider's View
- Introduction:
- Dr. Wu joined HMP in 2008 with 21 years of experience in drug discovery and development in the pharmaceutical and biotechnology industry. His past positions include Senior Director of Pharmaceutical Sciences at Phenomix Corporation, a California based drug discovery and development company, Director of Pharmaceutical Development at Pfizer Global Research & Development in San Diego, California (formerly Agouron Pharmaceuticals), and Senior Scientist at Roche at its Palo Alto site. Dr. Wu has led many development project teams and advanced numerous drug candidates into different phases of clinical development and commercialization including Sutent, a new blockbuster anti-cancer drug from Pfizer. Air Huarache Run Ultra BR
- Ms. Weijun SHA
- Company: TigerMed
- Title: BD Director & Project Director of TigerMed
- Topic: Creating New Valuable Working Model through Strategic Partnership with Clients
- Introduction:
- Over 15 years management experience in Medical, Medical Marketing, Marketing and Professional Marketing in A & Z, Roche and J & J;Medical Department Manager, AstraZeneca (1994.7-1997.7); Medical Manager and Senior Medical Marketing Manager，Shanghai Roche (1997.7 to 2006.3); Head of Professional Marketing Dept., Johnson & Johnson China Ltd.（2006.3-2007.12）; adidas Sneaker News
页面
Package Plan
Before 29/2/2012: USD 440
After 29/2/2012: USD 540
eve Conference Detail Testimonial
Chinese companies and academics reaching out to the western scientific community through attending meetings, publishing in scientific journals, etc is very important to address this problem. By not publishing more it is not only hurting China's growth but global growth as the opportunity to collaborate on research and find out about new discoveries is limited.
——Seth Goldenberg, President of Asia Pacific Bio Intelligence LLC
